Merck, CKT1MAG-97K-05, MILLIPLEX® Canine Kidney Toxicity Expanded Magnetic Bead Panel 1, CKT1MAG-97K

As one of the leading causes of drug candidate attrition, toxicity research is receiving more attention, especially in the search of sensitive, organ-specific toxicity biomarkers. In pharmaceutical and chemical industries, the kidney is routinely assessed during toxicity evaluations. The importance of the kidney as a central detoxification organ leads to a high exposure of renal tissue to drugs, reactive metabolites, and environmental compounds. Traditional markers for assessing renal toxicity, such as blood urea nitrogen (BUN) and serum creatinine, are insensitive and non-specific. For improved, non-invasive detection of acute nephrotoxicity, a panel of novel urinary kidney biomarkers has been identified and verified for preclinical studies in relevant animal species. The MILLIPLEX® portfolio provides a valuable research assay to investigate multiple biomarkers of kidney injury in canine urine samples using the Luminex® xMAP® instrument platform. The MILLIPLEX® Canine Kidney Toxicity Expanded Panel 1 is to be used for the simultaneous quantification of the following 7 analytes in any combination in canine urine samples: Clusterin, Cystatin C, Kidney Injury Molecule-1 (KIM-1), IL-8, Lipocalin-2/NGAL, MCP-1, and Osteopontin (OPN). This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls while can measure up to 38 samples in duplicate. The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume. Panel Type: Toxicity